Cantor Fitzgerald Weighs in on IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($2.60) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share.

IDYA has been the subject of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Leerink Partners cut IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. UBS Group began coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Stock Down 0.0 %

Shares of IDEAYA Biosciences stock opened at $23.14 on Wednesday. The stock has a market cap of $2.00 billion, a PE ratio of -9.93 and a beta of 0.82. The business has a fifty day simple moving average of $25.79 and a 200-day simple moving average of $32.07. IDEAYA Biosciences has a 12 month low of $22.10 and a 12 month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period in the prior year, the business earned ($0.46) EPS.

Hedge Funds Weigh In On IDEAYA Biosciences

Several institutional investors have recently bought and sold shares of IDYA. Envestnet Asset Management Inc. raised its holdings in IDEAYA Biosciences by 24.5% during the second quarter. Envestnet Asset Management Inc. now owns 104,553 shares of the company’s stock valued at $3,671,000 after buying an additional 20,607 shares in the last quarter. Renaissance Technologies LLC bought a new position in IDEAYA Biosciences during the second quarter valued at about $3,838,000. Hsbc Holdings PLC grew its position in shares of IDEAYA Biosciences by 80.1% in the second quarter. Hsbc Holdings PLC now owns 15,269 shares of the company’s stock valued at $528,000 after purchasing an additional 6,789 shares during the last quarter. Magnetar Financial LLC acquired a new stake in shares of IDEAYA Biosciences in the second quarter valued at about $1,599,000. Finally, Logos Global Management LP grew its position in shares of IDEAYA Biosciences by 13.3% in the second quarter. Logos Global Management LP now owns 1,700,000 shares of the company’s stock valued at $59,687,000 after purchasing an additional 200,000 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.